AACR 2023 | Overcoming resistance in lung cancer by targeting metabolic liabilities

Jaime Schneider, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the importance of targeting the metabolic pathway in targeted therapies. Whilst targeted therapies typically focus on signaling pathways, recent research relating to GUK1 have revealed the potential to exploit the metabolic pathways tumors use to expand. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.